Ubs Oconnor LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Ubs Oconnor LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.63 - $21.74 $109,782 - $135,374	-6,227 Reduced 6.18%	94,495 $1.86 Million
Q4 2023 Feb 14, 2024	SELL	$14.37 - $19.07 $81,923 - $108,718	-5,701 Reduced 5.36%	100,722 $1.77 Million
Q3 2023 Nov 14, 2023	SELL	$13.62 - $20.2 $1.57 Million - $2.32 Million	-115,000 Reduced 51.94%	106,423 $1.85 Million
Q2 2023 Aug 14, 2023	BUY	$10.44 - $16.48 $2.31 Million - $3.65 Million	221,423 New	221,423 $3.12 Billion
Q1 2023 May 15, 2023	BUY	$10.7 - $15.79 $633,953 - $935,525	59,248 Added 37.75%	216,210 $2.33 Million
Q4 2022 Feb 14, 2023	BUY	$11.42 - $17.05 $182,720 - $272,800	16,000 Added 11.35%	156,962 $0
Q3 2022 Nov 14, 2022	BUY	$9.76 - $13.41 $1.38 Million - $1.89 Million	140,962 New	140,962 $1.81 Billion

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.